The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer

The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus definitive therapy. In this retrospective cohort study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Helfand, Brian T., Paterakos, Michael, Wang, Chi-Hsiung, Talaty, Pooja, Abran, John, Bennett, John, Hall, David W., Lehman, Amy, Aboushwareb, Tamer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436076/
https://www.ncbi.nlm.nih.gov/pubmed/36048818
http://dx.doi.org/10.1371/journal.pone.0273782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436076/
https://www.ncbi.nlm.nih.gov/pubmed/36048818
http://dx.doi.org/10.1371/journal.pone.0273782

Ejemplares similares